Discovery of M Protease Inhibitors Encoded by SARS-CoV-2-Reference-Cited by-同舟云学术

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hung Hui-Chen¹,Ke Yi-Yu¹,Huang Sheng Yu²,Huang Peng-Nien²³,Kung Yu-An²³,Chang Teng-Yuan¹,Yen Kuei-Jung¹,Peng Tzu-Ting⁴,Chang Shao-En¹,Huang Chin-Ting¹,Tsai Ya-Ru¹,Wu Szu-Huei¹,Lee Shiow-Ju¹,Lin Jiunn-Horng⁴,Liu Bing-Sin⁵,Sung Wang-Chou⁵,Shih Shin-Ru²⁶^ORCID,Chen Chiung-Tong¹,Hsu John Tsu-An¹⁷^ORCID

Affiliation:

1. Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan

2. Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan

3. Division of Infectious Diseases, Department of Pediatrics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

4. Department of Animal Technology Laboratories, Agricultural Technology Research Institute (ATRI), Miaoli, Taiwan

5. National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan

6. Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

7. Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan

Abstract

The coronavirus (CoV) disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is a health threat worldwide. Viral main protease (M pro , also called 3C‐like protease [3CL pro ]) is a therapeutic target for drug discovery. Herein, we report that GC376, a broad-spectrum inhibitor targeting M pro in the picornavirus-like supercluster, is a potent inhibitor for the M pro encoded by SARS-CoV-2, with a half-maximum inhibitory concentration (IC 50 ) of 26.

Funder

Ministry of Science and Technology, Taiwan

Ministry of Education

MOHW | Health Promotion Administration, Ministry of Health and Welfare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00872-20

Reference31 articles.

1. The SARS-CoV-2 outbreak: What we know